Hepatic angiotensinogen-lowering RNA therapeutics
Hepatic angiotensinogen-lowering RNA therapeutics has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 2, 2026: “Hepatic Angiotensinogen-Lowering RNA Therapeutics for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”.
1 paper studies it3 findingsUpdated
1 new paper in 30 daysSee all 1 papers on hepatic angiotensinogen-lowering RNA therapeutics
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
What did studies of hepatic angiotensinogen-lowering RNA therapeutics find?
2Studies of hepatic angiotensinogen-lowering RNA therapeutics measured 2 outcomes: circulating angiotensinogen and 24-hour ambulatory systolic blood pressure.
Circulating angiotensinogen
downin humans1
1 study
Circulating angiotensinogen
downin humans1
Hepatic angiotensinogen-lowering RNA therapeutics decrease circulating angiotensinogen in humans (hypertension; versus control) (MD –66.82%; 95% CI –92.71 to –40.92).
“Circulating AGT was also significantly reduced (MD –66.82%; 95% CI –92.71 to –40.92).”
Reviewhypertension; versus control
AHA Scientific Sessions 2026 abstract
24-hour ambulatory systolic blood pressure
downin humans1
1 study
24-hour ambulatory systolic blood pressure
downin humans1
Hepatic angiotensinogen-lowering RNA therapeutics decrease 24-hour ambulatory systolic blood pressure in humans (hypertension; versus control) (MD –13.16 mmHg; 95% CI –18.70 to –7.63).
“Hepatic AGT-lowering RNA therapeutics significantly reduced 24-hour ambulatory systolic blood pressure measured by ambulatory blood pressure monitoring at approximately 3 months versus control”
Reviewhypertension; versus controlapproximately 3 months
AHA Scientific Sessions 2026 abstract
What is hepatic angiotensinogen-lowering RNA therapeutics linked with?
1Studies link hepatic angiotensinogen-lowering RNA therapeutics with hyperkalemia.
Hyperkalemia
upin humans1RR 2.8
1 study
Hyperkalemia
upin humans1RR 2.8
Hepatic angiotensinogen-lowering RNA therapeutics raise the risk of hyperkalemia in humans (hypertension; versus control) (RR 2.80; 95% CI 1.30 to 6.04).
“Hyperkalemia was more frequent with RNA therapeutics (RR 2.80; 95% CI 1.30 to 6.04)”
Reviewhypertension; versus control
AHA Scientific Sessions 2026 abstract